Marinomed Biotech has announced that Fidia Farmaceutici will begin marketing Marinomed’s Carragelose-based nasal sprays in Italy in Fall 2020, and Sanova Pharma has signed an agreement to launch the new Carravin nasal spray in Austria in 2021, subject to approval.
The company’s Carregelose products are already available in a number of European countries, as well as Canada, China, Australia, and several additional countries. In the announcement, Marinomed noted that it is also expanding development of products based on its Marinosolv platform, which includes Budesolv budesonide nasal spray.
In April 2020, Marinomed said that it had received funding for a Phase 1 study of a new Carragelose inhalation solution for the treatment of pneumonia associated with COVID-19. The company now says that preparations for the trial are underway, and Chief Scientific Officer Eva Prieschl-Grassauer clarifies that “This is to test both the effectiveness of the Carragelose polymer on SARS-CoV-2 and other viruses of the respiratory tract.”
Read the Marinomed press release.
